Empreses emergents
2020
BSURE MEDICAL SLUn gran pas endavant cap a la seguretat dels bioimplants Podem identificar persones que tenen un risc molt alt de patir efectes adversos tardans greus si s'utilitzen farciments dèrmics.
Adreça
08940 Barcelona, Espanya
Propietat CERCA
Barcelona, Spain
2002
Vall d’Hebron Institut de Recerca (VHIR)
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
The creation of BSURE Medical represents the culmination of the valuation and transfer strategy carried out by the VHIR Innovation Unit of a research project of which Dr. Jaume Alijotas Reig and Dr. Simo Schwartz Jr are the main researchers and promoters.
The groups of Dr. Alijotas and Dr. Schwartz Jr have developed a procedure that makes it possible to reliably and easily determine the risk of suffering serious late-onset immune, local, regional or systemic adverse effects (edema, angioedema, induration of skin, multiple inflammatory nodules, panniculitis, even granulomatous or autoimmune diseases…) after implantation of an injectable biomaterial, such as dermal or subcutaneous fillers.
The groups of Dr. Alijotas and Dr. Schwartz Jr have developed a procedure that makes it possible to reliably and easily determine the risk of suffering serious late-onset immune, local, regional or systemic adverse effects (edema, angioedema, induration of skin, multiple inflammatory nodules, panniculitis, even granulomatous or autoimmune diseases…) after implantation of an injectable biomaterial, such as dermal or subcutaneous fillers.
Descripció del producte
The creation of BSURE Medical represents the culmination of the valuation and transfer strategy carried out by the VHIR Innovation Unit of a research project of which Dr. Jaume Alijotas Reig and Dr. Simo Schwartz Jr are the main researchers and promoters.
The groups of Dr. Alijotas and Dr. Schwartz Jr have developed a procedure that makes it possible to reliably and easily determine the risk of suffering serious late-onset immune, local, regional or systemic adverse effects (edema, angioedema, induration of skin, multiple inflammatory nodules, panniculitis, even granulomatous or autoimmune diseases…) after implantation of an injectable biomaterial, such as dermal or subcutaneous fillers. This risk is strongly associated with the presence of certain antigen profiles in a biological sample of the individual, which allows them to be easily identified from the analysis of blood or saliva samples. "With this procedure we can identify people who have a very high risk of suffering serious late adverse effects if dermal fillers are injected and, therefore, it is a very useful predictive and preventive tool", says Dr. Alijotas, scientific advisor of the company.
The technology is patented and has been validated in two independent clinical trials coordinated by the Systemic Autoimmune Diseases Unit of the Vall d'Hebron University Hospital in Barcelona and by the Dermatology Department of the Erasmus Medical Center, Rotterdam and the Department of Plastic Surgery, VU University Medical Center, Amsterdam. The VHIR has granted BSURE a license to use and exploit it exclusively and worldwide. The patent has already been granted in Europe, Brazil and Japan.
The groups of Dr. Alijotas and Dr. Schwartz Jr have developed a procedure that makes it possible to reliably and easily determine the risk of suffering serious late-onset immune, local, regional or systemic adverse effects (edema, angioedema, induration of skin, multiple inflammatory nodules, panniculitis, even granulomatous or autoimmune diseases…) after implantation of an injectable biomaterial, such as dermal or subcutaneous fillers. This risk is strongly associated with the presence of certain antigen profiles in a biological sample of the individual, which allows them to be easily identified from the analysis of blood or saliva samples. "With this procedure we can identify people who have a very high risk of suffering serious late adverse effects if dermal fillers are injected and, therefore, it is a very useful predictive and preventive tool", says Dr. Alijotas, scientific advisor of the company.
The technology is patented and has been validated in two independent clinical trials coordinated by the Systemic Autoimmune Diseases Unit of the Vall d'Hebron University Hospital in Barcelona and by the Dermatology Department of the Erasmus Medical Center, Rotterdam and the Department of Plastic Surgery, VU University Medical Center, Amsterdam. The VHIR has granted BSURE a license to use and exploit it exclusively and worldwide. The patent has already been granted in Europe, Brazil and Japan.